Purulent-inflammatory diseases are widespread and account for 1/3 of all surgical pathology. A severe life-threatening condition is the development of sepsis, with a mortality rate of up to 43 %. The aim of the study was to compare the dynamics of the course of thrombohemorrhagic syndrome with the use of cryosupernatant plasma fraction and freshly frozen plasma in patients with phlegmon and sepsis. Two groups of patients with phlegmon of soft tissues and sepsis were formed. Cryosupernatant plasma fraction transfusions were performed in the main group (34 patients, 47.9 %) as part of cryoplasma–enzyme therapy, and in the comparison group (37 patients, 52.1 %) with freshly frozen plasma. A study of hemostasis parameters indicated the presence of tombohemorrhagic syndrome. The effectiveness of the therapy was evaluated 8–10 days after its start. The addition of complex therapy with cryosupernatant plasma fraction contributes to more effective relief of thrombohemorrhagic syndrome compared with the use of freshly frozen plasma and improved treatment results, which is manifested in accelerated wound cleansing and filling with granulation tissue for 3.7 days, a 1.7-fold reduction in mortality, and the absence of complications of the septic process of a thrombotic or thromboembolic nature.